Navigation Links
ESBATech's Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops

Preclinical results to be presented at two international scientific


ZURICH, Switzerland, Feb. 25 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced that it has achieved high concentrations of its antibody fragments in all segments of the eye with topical delivery via eye drops. These data were confirmed in several independent preclinical in vivo tests. Anticipated therapeutic concentrations of ESBATech's antibody fragments were observed in the anterior chamber (front of the eye) and in the posterior segments (back of the eye) including vitreous humour, retina, and choroid. ESBATech's lead antibody fragment ESBA105 is a TNFa antagonist that is scheduled to enter clinical development later in 2008.

(Photo: )

ESBATech also announced today that it will present its preclinical eye penetration data at two upcoming scientific conferences. Dominik Escher, Ph.D., ESBATech's Chief Executive Officer will present at Antibody Engineering Asia in Singapore on February 26, 2008. David Urech, Ph.D., Head of Research & Development at ESBATech will present at the ISOPT 2008 (International Symposium on Ocular Pharmacology and Therapeutics) in Budapest on February 29, 2008.

Dr. Urech commented, "ESBATech's proprietary, repeatable screening platform was employed and generated multiple promising antibody fragment product candidates against several targets for topical ophthalmic use. Antibody fragments have a number of advantages over whole antibodies, resulting from their smaller molecular size. The primary advantage of human antibody fragment is their ability to penetrate tissues much better than whole antibodies. We believe that with our highly stable and monomeric single-chain antibody fragments, we now meet the protein requirements that allow for sufficient delivery of immune binders into all segments of the eye via eye drops."

Dr. Escher added, "These exciting results provide the basis to proceed into clinical development later this year. Based on these pharmacodynamic properties, in combination with the reported concentrations of relevant cytokines from patients, we are confident that we can hit the therapeutic window in the chosen ophthalmic indication."

About Antibody Fragments

Antibody fragments are an emerging area of focus within the monoclonal antibody market and represent a new class of therapeutics. Due to their smaller molecular size, antibody fragments have a number of advantages over whole antibodies. Antibody fragments comprise only the naturally occurring antigen-binding pocket of the monoclonal antibody, and not the Fc part that is required to trigger an immune response. This new class of new products opens applications which are advantageous compared to monoclonal antibodies in indications where no such immune response is required. Thus, endogenous proteins are preferred targets for these new biologics.

About ESBATech AG

ESBATech AG is a Zurich, Switzerland-based, privately held drug discovery and development company focused on advancing antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery. Current venture investors include SV Life Sciences, Clarus Ventures, HBM BioVentures, HBM BioCapital, Novartis Venture Fund, BioMedinvest and VI Partners. For more information about ESBATech, please visit,

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility
2. Vaccinex Antibody Licensed to GlaxoSmithKline
3. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
4. Human Genome Sciences and Xencor Announce Antibody Collaboration
5. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
6. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
7. Roche Files IND for Second Genmab Antibody
8. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
9. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
10. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
11. Vaccinex, Inc. Announces Award of Key Patent in Europe for its Antibody Discovery Technology (ActivMab(R))
Post Your Comments:
(Date:10/13/2015)... the United States , Canada ... of all new cases of kidney cancer.   --> ... and Europe .  PRCC represents about 14% of ... China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Hutchison MediPharma ... have completed enrolment in a global Phase II study of savolitinib ...
(Date:10/12/2015)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the leading ... processes to develop and market advanced products and therapies ... Ophthalmic, and the Dental sectors of healthcare, announced today ... the Company has been dismissed by the court.  ... stated, "As we suspected, this case was brought by ...
(Date:10/12/2015)... , October 12, 2015 cell surface ... billion by 2022, according to a new report by Grand ... to rise in incidence of oncology diseases and other cell-associated ... is expected to reach USD 6.49 billion by 2022, according ... growth in demand can be attributed to rise in incidence ...
(Date:10/12/2015)... SAN DIEGO , Oct. 12, 2015 /PRNewswire/ ... for debilitating allergic and inflammatory diseases and conditions, ... Series A preferred stock financing. Concurrent with the ... also entered into a Loan and Security Agreement ... borrow up to $7 million. Patara will use ...
Breaking Biology Technology:
(Date:9/29/2015)... 2015 News facts: ... saving energy , Minimized design shrinks PC footprint ... Mode and embedded Fujitsu PalmSecure authentication enable enterprises to ... today shows that good things come in small packages, ... its enterprise desktop and mobile portfolio. Featuring workplace design ...
(Date:9/28/2015)... 28, 2015 CLEAR, the leading ... expedited traveler service is coming to Austin-Bergstrom ... bringing a frictionless experience, serious speed and ... "CLEAR offers our travelers an expedited security ... Jim Smith , Executive Director, Austin-Bergstrom ...
(Date:9/28/2015)... 2015 The global image ... 12.03 billion by 2020, growing at a CAGR of ... Backside Illumination (BSI) technique to improve picture quality are ...      (Logo: , The ... reduce loss and, thus, reduce the noise interference and ...
Breaking Biology News(10 mins):